Quantcast

Latest autoimmune diseases Stories

2014-09-18 23:03:16

Arthritis Society says patient safety paramount as new class of medications become available Toronto, ON (PRWEB) September 18, 2014 With the arrival of subsequent-entry biologics (SEBs) set to alter the arthritis treatment landscape, The Arthritis Society released new resources to educate stakeholders on their potential impact. The bottom line: safety and strong public policy must guide SEB use, and patients must be well informed when speaking to their healthcare team. Click here for an...

2014-09-18 04:21:05

Company Recently Initiated Phase II in Bullous Pemphigoid CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Sept. 18, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). Dr. Daniel Teper, Chairman and CEO of Immune comments: "Bertilimumab is...

2014-09-17 12:25:34

Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that among Crohn's disease/ulcerative colitis (CD/UC) patients eligible for biologic therapy, only a proportion of patients currently receive a biologic. Surveyed gastroenterologists cite patients' discomfort with biological therapy as the...

2014-09-15 12:27:50

Hundreds Step Up For New Lupus Treatments NEW YORK, Sept. 15, 2014 /PRNewswire/ -- Over 200 patients, families, physicians and scientists came together under one roof Saturday to learn, interact and participate in the drive for better lupus treatments at New York City's first Lupus Trials Fair launched by the Lupus Research Institute (LRI) and the S.L.E. Lupus Foundation. Attendees interacted directly with researchers at eight of NYC's leading institutions -- sharing experiences,...

2014-09-12 08:25:21

- Research grants awarded for five out of more than 200 proposals, highlighting continued commitment to multiple sclerosis (MS) ROCKLAND, Mass., Sept. 12, 2014 /PRNewswire/ -- EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the recipients of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and...

2014-09-11 04:21:10

- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA(®) (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-09-09 12:28:50

Lupus Foundation of America and Rheumatology Research Foundation hold congressional briefing WASHINGTON, Sept. 9, 2014 /PRNewswire-USNewswire/ -- Today, the Lupus Foundation of America, the only national force devoted to solving the mystery of lupus, and the Rheumatology Research Foundation, the largest private funding source of rheumatology research and training programs, convened on Capitol Hill to update our nation's leaders about the new Accelerating Medicines Partnership (AMP)...

2014-09-09 08:30:24

ORLANDO, Fla. and DUBLIN, Sept. 9, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company"), a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced the results of its 2014 annual general meeting of shareholders. The shareholders of the Company have approved all the matters submitted to them at the Company's 2014 annual general meeting held at 10:00 a.m., Eastern...

2014-09-04 12:26:34

DIEPENBEEK, Belgium, September 4, 2014 /PRNewswire/ -- Scientists discover how to 'switch off' autoimmune diseases Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that Bristol University research led by Apitope Founder and CSO, Prof David Wraith, on its treatment approach to autoimmune diseases, such as Multiple Sclerosis (MS), has been published...

2014-09-01 04:20:02

A*STAR scientists find new targets for modulating antibody response Singapore, Sept 1, 2014 - (ACN Newswire) - Scientists from A*STAR's Bioprocessing Technology Institute (BTI) have uncovered the crucial role of two signalling molecules, DOK3 and SHP1, in the development and production of plasma cells. These discoveries, published in two prestigious journals PNAS and Nature Communications, advance the understanding of plasma cells and...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.